Advisory Board and Editors Pharmacology
Jiangjiang Qin
Dr. Jiangjiang Qin is currently a Professor of Cancer Pharmacology and Drug Discovery at the Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences and the Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital).
Dr. Qin received his B.S. degree in Pharmacy (2006) and Ph.D. in Biomedical Engineering with the highest honor (2011) from Shanghai Jiao Tong University, China, under the supervision of Professor Wei-Dong Zhang. After completion of Post-Doctoral training in cancer biology, pharmacology, and molecular therapeutics at Texas Tech University Health Sciences Center (TTUHSC) in 2014, Dr. Qin continued his research work at TTUHSC as a Research Associate and a Senior Research Associate and at the University of Houston as a Senior Research Scientist. Dr. Qin joined Zhejiang Chinese Medicinal University as a Full Professor in 2018 and then moved to IBMC in 2020.
Dr. Qin’s research mainly focuses on the discovery and development of novel, effective, and safe anticancer agents as well as demonstrating the molecular targets and mechanisms of action. He has published more than 150 research papers and reviews. He is also an Associate Editor of Frontiers in Pharmacology and Frontiers in Oncology and an Editorial Board Member of more than 10 scientific journals such as Recent Patents on Anti-Cancer Drug Discovery, Journal of Cancer Research Updates, World Journal of Traditional Chinese Medicine.
Silvia Rivara
Professor of Medicinal Chemistry, University of Parma, Italy.
My research interests are related to drug design, structure-activity relationships and molecular modelling applied to compounds of pharmaceutical interest.
Joao B.T. Rocha
Professor of Biochemical Toxicology at the Universidade Federal de Santa Maria-Department of Biochemistry and Molecular Biology CCNE, 97105-900, Santa Maria, RS, Brazil. Associate Regular Member of International Centre for Theoretical Physics, Trieste.
Michael A. Rogawski
Professor, Department of Neurology, School of Medicine; Pharmacology and Toxicology Graduate Group; Center for Neuroscience; University of California, Davis. Past president, American Society for Experimental NeuroTherapeutics. Academic editor of 9 journals. Co-founder of Epilepsy Currents, the journal of the American Epilepsy Society.
I received a B.A. (biophysics) from Amherst College, and M.D. and Ph.D. (pharmacology) degrees from Yale University. I was a resident, fellow and assistant professor in the Department of Neurology at the Johns Hopkins University School of Medicine. For over 20 years, I was a senior investigator and chief of the Epilepsy Research Section at the National Institute of Neurological Disorders and Stroke. My research interests involve ion channel pharmacology and neurological therapeutics, including antiepileptic drugs and other epilepsy treatment approaches.
Rebecca H Roubin
Lecturer in Pharmaceutical and Medicinal Chemistry, University of Sydney
Member, Cancer Research Network
Past Vice-President, Sydney Tissue Engineering and Matrix (STEAM) interest group
Member, Antler Science and Product Technology Society International (ASPTS)
Member, Matrix Biology Society of Australia and New Zealand (MBSANZ)
Past-President, Royal North Shore Hospital Postgraduate Research Students’ Society
J. Thomas Sanderson
Professor of Toxicology at the INRS-Institut Armand-Frappier, Université du Québec, Laval, Canada. Adjunct professor at the Department of Pharmacology and Therapeutics, Faculty of Medicine, McGill University, Montréal, Canada. Member and former councillor (2008-2011) of the Society of Toxicology of Canada. Member of the Society of Toxicology since 2000. Recipient of a 2006 Leader's Opportunities Fund Infrastructure Award from the Canadian Foundation for Innovation. Current research funded by the Canadian Institutes of Health Research and Natural Sciences and Engineering Council of Canada.
Michael F Santillo
I have over a decade of experience leading independent laboratory research projects as a research chemist at the U.S. Food and Drug Administration (FDA). The focus of my work is using in silico (computational tools, especially QSAR) and in vitro (cellular and biochemical) methods for identifying chemical hazards associated with foods and dietary supplements.
Fatima Saqib
Dr. Fatima Saqib, has a PhD in Pharmacology from Bahauddin Zakariya University. Currently, she is serving as Professor (Assistant) in BZU, Multan. Previously she served as Lecturer for 8 years. She has supervised 34 M.Phil students and 5 PhD students under supervision. She has published 38 international research articles and review paper with a total IF120 with h-index 12, i-index 16 and total google scholar citations 437.
Susanne Schmid
Susanne Schmid is an Associate Professor at the University of Western Ontario. Her research focuses on sensory information processing and sensory gating mechanisms. She uses mainly rodents to explore synaptic mechanisms and neuronal circuits underlying sensory gating in healthy subjects and in animal models for schizophrenia and autism.
Mirela Sedic
Dr Mirela Sedic (born Bauman) is Principal Scientist at the Institute for Anthropological Research Zagreb. She has authored over 50 scientific publications in peer-reviewed journals including high-impact journals such as BBA Molecular Basis of Disease, Molecular Cancer, The Journal of Pathology, Molecular Cancer Therapeutics, Journal of Medicinal Chemistry, European Journal of Medicinal Chemistry and Cancer Treatment Reviews.
She was the co-PI of international collaborative project with Functional Genomics Center Zurich in Switzerland (PRIME-XS-0000184 Proteomic profiling of retinal proteins from rat model of age-related macular degeneration 2012-2014) and the PI of the University of Rijeka grant “Screening and biological evaluation of acid ceramidase and sphingosine kinase inhibitors as a new class of anti-tumour agents” (2014 – 2017). She is currently the PI of the project funded by the Croatian Science Foundation “Dissecting the mechanisms of therapy resistance in BRAF-mutant colon cancer using an integrated –omics approach” (2019 – 2023) and the PI of the University of Rijeka research grant “Molecular features associated with BRAFV600E-mutated versus wild type BRAF colorectal cancer” (2019-2022). She is also the PI of the project No. 3238 - EPIC-XS 012: “Proteomic analysis of acquired resistance to vemurafenib in BRAF V600E–mutant colon cancer cells” (2019 - 2022) in collaboration with the Functional Genomics Center Zurich in Switzerland.
Rajesh Kumar Singh
Dr. Rajesh Kumar Singh received his BPharm (2003) and MPharm (2005) from UIPS, Panjab University, Chandigarh. He started to teach pharmaceutical chemistry at the Shivalik College of Pharmacy, Nangal, in 2006, where he completed his PhD in 2013 from IKG Punjab Technical University (IKGPTU), Jalandhar. His major areas of research interest are computer-aided drug-design, polymer-drug conjugates for targeted delivery to CNS and cancerous cells, antimalarial therapeutic agents, and green chemistry approaches for chemical synthesis. Dr. Singh has over 15 years of teaching experience and has guided one 03 Ph.D. and 20 PG students. He is currently guiding 02 PhDs and 02 MPharm students. He has published more than 70 peer-reviewed SCI/SCOPUS-indexed scientific papers with a total JCR Impact Factor of more than 200 in various chemistry and pharmacy journals such as European Journal of Medicinal Chemistry, Acta Pharmaceutica Sinica-B, Bioorganic Chemistry, Biomedicine and Pharmacotherapy, Pharmaceutical Research, European Journal of Pharmaceutical Sciences, Mini-Reviews in Medicinal Chemistry, Pharmaceutical Research, Med. Chem. Res., J. Enzyme Inhi. Med Chem., Res. Chem. Intermediate etc as main or corresponding author. He currently serves as an Editorial Advisory Board Member of 10 international journals, including the SCI-indexed MRMC (Bentham) and PeerJ. He has received the Publon Award 2016, 2017 and the Publon "Excellent Peer Reviewer Award" for outstanding reviewing of more than 290 research papers in different international journals of ACS, RSC, Springer, Elsevier, Dove, Informa, and Bentham whose Impact Factor varies from 1.0 to 12.5. He also has over 60 National and International Conference Abstracts, 5 Books, 5 Best Paper Presentation Awards, 1 Travel Grant to attend International Conferences, and 5 Research Projects funded by Indian Government Agencies. He is also on the panel of international reviewers for research proposals for Royal Society Grants. He is also serving as a PUBLON ACADEMY MENTOR and a BENTHAM BRAND AMBASSADOR. He has been recognized by the Editors as an OUTSTANDING REVIEWER for RSC Medicinal Chemistry journal (IF 4.1, Q1) and also for BENTHAM PUBLISHER in 2023. His name is recently featured in the list of top 2% scientists (2023) ranked by team of Stanford University, USA and Elsevier.
Srinivas Sistla
Dr. Srinivas Sistla is Director of Laboratories within the Microbiology and Immunology Department at State University of New York (SUNY) Stony Brook. He is a trained Biophysics and Drug Discovery Scientist, with experience working for industry and academia.
Dr. Sistla obtained his PhD in 2008 (Biotechnology and Biophysics) and is interested in the following fields of research; Bioactive Peptides, Biochemistry, Biophysics, Medical Biochemistry and Metabolomics, and Surface Plasmon Resonance.